Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-09-20
2005-09-20
Nickol, G. (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C436S500000, C436S501000, C436S512000, C424S130100, C424S131100, C424S134100, C424S135100
Reexamination Certificate
active
06946256
ABSTRACT:
This application describes the cloning of p63, a gene at chromosome 3q27-29, that bears homology to the tumor suppressor p53. The p63 gene encodes at least six different isotypes. p63 was detected in a variety of human and mouse tissue and demonstrates remarkably divergent activities, such as the ability to transactivate p53 reporter genes and induce apoptosis. Isotopes of p63 lacking a transactivation domain act as dominant negatives towards the transactivation by p53 and p63.
REFERENCES:
patent: 6518256 (2003-02-01), Wang et al.
patent: 377295 (1990-07-01), None
patent: 2 692 594 (1993-12-01), None
patent: WO 94/01563 (1994-01-01), None
patent: WO 94/08241 (1994-04-01), None
patent: WO 97/28186 (1997-08-01), None
patent: WO 99/19357 (1999-04-01), None
Pujol et al (Proc Amer Ass of Cancer Res Ann Meeting 1994; 35(0):165)-Abstract only.
Li et al (Zhonghua Zhongliu Zazhi 1994; 16(3):172-176)-Abstract only.
Righi E et al. (Diagn Cytopathol Dec. 17, 1997(6):436-9.
Hall et al. (Carcinogenesis Feb. 21, 2000(2):153-60).
Parsa R et al. (J. Invest Dermatol Dec. 1999: 113(6):1099-1105).
Baylin et al., “Killer/DR5 is a DNA damage-inducible p53-regulated death receptor gene,” Nature Genetics, 17:141-142 (1997).
Beaudry et al., “Therapeutic targeting of the p53 tumor suppressor gene,” Pharmaceutical Biotechnology, 592-600.
Cviko et al., “Adenoid basal carcinomas of the cervix: a unique morphological evolution with cell cycle correlates,” Hum Pathol., 31(6):740-744 (2000).
Damiani et al., “Myoepithelial cells and basal lamina in poorly differentiated in situ duct carcinoma of the breast,” Virchows Arch, 434:27-234 (1999).
De Laurenzi et al., “Evolution of Functions within the p53/p63/p73 Family,” Ann N Y Acad Sci., 926:90-100 (2000).
Foschini et al., “Carcinomas of the breast showing myoepithelial cell differentiation,” Virchows Arch, 432:303-310 (1998).
Friedman et al., “The p53 protein is an unusually shaped tetramer that binds directly to DNA,” Proc. Natl. Acad. Sci., 90:3319-3323 (1993).
Huibregtse et al., “A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18,” The EMBO Journal, 10( 13):4129-4135 (1991).
Huibregtse et al., “Cloning and Expression of the cDNA for E6-AP, a Protein that Mediates the Interaction of the Human Papillomavirus E6 Oncoprotein with p53,” Molecular and Cellular Biology, 13(2):775-784 (1993).
Ince et al., “p63 Coordinates Anogenital Modeling and Epithelial Cell Differentiation in the Developing Female Urogenital Tract,” Am Journal of Pathol., 161(4):1111-1117 (2002).
Lazar et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,” Molecular and Cellular Biology, 8(3):1247-1252 (1988).
Le Bras et al., “Monoclonal antibodies raised against Xenopus p53 interact with human p73,” Oncogene, 21:1304-1308 (2002).
Levero et al., “The p53/p63/p73 family of transcription factors: overlapping and distinct fumctions,” J Cell Sci. 113:1661-1670 (2000).
Lohrum et al., “Regulation and function of the p53-related proteins: same family, different rules,” Trends Cell Biol., 10(5):197-202 (2000).
Mills et al., “p63 is a p53 homologue required for limb and epidermal morphogenesis,” Nature, 398:708-713 (1999).
Nayar et al., “Immunoreactivity of ductal cells with putative myoepithelial markers: a potential pitfall in breast carcinoma,” Ann Diagn Pathol., 3:165-173 (1999).
O'Connell et al., “Identification of a Basal/Reserve Cell Immunophenotype in Benign and Neoplastic Endometrium: A Study with the p53 Homologue p63,” Gynecol Oncol., 80(1):30-36 (2001).
Osada et al., “Cloning and functional analysis of human p51, which structurally and functionally resembles p53,” Nat Med., 4(7):839-843 (1998).
Quade et al., “Expression of the p53 Homologue p53 in Early Cervical Neoplasia,” Gynecol Oncol, 80(1):24-29 (2001).
Ramnani et al., “Basal Cell-Specific Anti-Keratin Antibody 34βE12: Optimizing Its Use in Distinguishing Benign Prostate and Cancer,” Mod. Pathology, 12:443-444 (1999).
Sakamoto et al., “Specific sequences from the carboxyl terminus of human p53 gene product form anti-parallel tetramers in solution,” Proc. Natl. Acad. Sci., 9:8974-8978 (1994).
Scheffner et al., “Interaction of the Human Papillomavirus Type 16 E6 Oncoprotein with Wild-Type and Mutant Human p53 Proteins,” Journal of Virology, 66(8):5100-5105 (1992).
Scheffner et al., “The HPV-16E6 and E6-AP Complex Functions as a Ubiquitin-Protein Ligase in the Ubiquitination of p53,” Cell, 75.495-505 (1993).
Schweizer et al., “A reversibly palmitoylated resident protein (p63) of an ER-Golgi intermediate compartment is related to a circulatory shock resuscitation protein,” Journal of Cell Science, 4:685-694 (1993).
Senoo et al., “A Second p53-Related Protein p73L, with High Homology to p73,” Biochem Biophys Res Commun., 248(3):603-607 (1998).
Signoretti et al., “Basal Cell Specific p63 is Useful in the Differential Diagnosis of benign vs. Malignant Lesions of the Prostate,” Presentation at the United States and Canadian Academy of Pathology (USCAP), Mar. 29, 2000.
Signoretti et al., “p63 Is a Prostate Basal Cell Marker and is Required for Prostate Development,” Am Journal of Pathol., 157(6):1769-1775 (2000).
Sternlicht et al., “The Human Myoepithelial Cell Is a Natural Tumor Suppressor,” Clin Cancer Research, 3:1949-1958 (1997).
Theis et al., “A function in apoptosis other than transactivation inherent in the NH2-terminal domain of p53,” International Journal of Cancer, 71:858-866 (1997).
Totten et al., “Microscopic Differential Diagnosis of Latent Carcinoma of Prostate,” Arch Pathol., 55:131-141 (1953).
Trink et al., “A new human p53 homologue,” Nat. Med. 4(7):747-748 (1998).
Urist et al., “Loss of p63 Expression is Associated with Tumor Progression in Bladder Cancer,” Am Journal of Pathol., 161(4): 1199-1206 (2002).
Varma et al., “Discriminant staining patterns of small glandular and preneoplastic lesions of the prostate using high molecular weight cytokeratin (HMCK)—A study of 301 consecutive needle biopsies,” Abstract, Mod Pathol., 1997, 10:93A.
Varma et al., “Effect of Formalin Fixation and Epitrope Retrieval Techniques on Antibody 34βE12 Immunostaining of Prostatic Tissues,” Mod Pathol., 12:472 (1999).
Wang et al., “Histologic and Immunophenotypic Classification of Cervical Carcinomas by Expression of the p53 Homologue p63: A Study of 250 Cases,” Hum Pathol., 32(5):479-486 (2001).
Yang et al., “Lineage-specific expression of the P53 homologue P63 in genital tract neoplasia,” Abstract, Mod Pathol., Jan. 1999, 127A.
Yang et al., “P63: a P53 homologue that is a differentiation-specific marker in cervical squamous epithelium,” Abstract, Mod Pathol., Jan. 1999, 178A.
Yang et al., “Rare Expression of High-Molecular-Weight Cytokeratin in Adenocarcinoma of the Prostate Gland,” Am J Surg Pathol., 23(2):147-152 (1999).
Zeng et al., “NBP is the p53 homolog p63,” Carcinogenesis, 22(2):215-219 (2001).
Desquiedt et al., “Nucleotide Sequence of the Bovine p53 Tumor-Suppressor cDNA,”DNA Seq. 5(4): 261-264 (1995).
Gryaznov et al., “Selective O-Phosphitilation With Nucleoside Phosphoramidite Reagents,”Nucleic Acids Research, 20(8):1879-1882 (1992).
Iwase et al., “Identification of Protein-Tyrosine Kinase Genes Preferentially Expressed in Embryo Stomach and Gastric Cancer,”Biochemical&Biophysical. Research. Communications., 194(2):698-705 (Jul. 1993).
McNaughton et al., “A Cluster of Transposon-Like Repetitive
Crum Christopher
Loda Massimo
McKeon Frank
Signorretti Sabina
Yang Annie
Dana-Farber Cancer Institute Inc.
Foley & Hoag LLP
Nickol G.
President & Fellows of Harvard College
The Brigham and Women's Hospital, Inc.
LandOfFree
Cell regulatory genes, encoded products, and uses related... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cell regulatory genes, encoded products, and uses related..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell regulatory genes, encoded products, and uses related... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3372222